Real-time Estimate Cboe BZX 02:42:28 2024-04-19 pm EDT 5-day change 1st Jan Change
11.34 USD -1.00% Intraday chart for Zynex, Inc. -4.62% +4.32%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
RBC Raises Price Target on Zynex to $15 From $13, Keeps Outperform Rating MT
Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024 CI
Tranche Update on Zynex, Inc.'s Equity Buyback Plan announced on September 11, 2023. CI
Tranche Update on Zynex, Inc.'s Equity Buyback Plan announced on November 1, 2023. CI
Zynex, Inc. announces an Equity Buyback for $20 million worth of its shares. CI
Transcript : Zynex, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Earnings Flash (ZYXI) ZYNEX Reports Q4 Revenue $47.3M, vs. Street Est of $55.6M MT
Zynex, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Zynex, Inc. authorizes a Buyback Plan. CI
Zynex, Inc. Introduces New Products CI
Zynex Receives US FDA Approval for Muscle Stimulation Device MT
Zynex, Inc. Receives FDA Clearance for its Next Generation NMES Device CI
Zynex, Inc.'s Equity Buyback announced on September 11, 2023, has closed with 1,161,536 shares, representing 3.3% for $10 million. CI
Zynex Submits FDA Application for M-Wave Neuromuscular Electrical Stimulation Device MT
Zynex, Inc. Submits FDA Application for Its NMES Device CI
Zynex to Repurchase Up to $20 Million Common Shares Through Nov. 1, 2024 MT
Zynex, Inc. announces an Equity Buyback for $20 million worth of its shares. CI
Zynex, Inc. authorizes a Buyback Plan. CI
Zynex Board Initiates Review of Strategic Options Including Sale, Merger MT
Zynex Announces Review of Strategic Alternatives CI
Tranche Update on Zynex, Inc.'s Equity Buyback Plan announced on September 11, 2023. CI
Tranche Update on Zynex, Inc.'s Equity Buyback Plan announced on June 14, 2023. CI
Zynex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Zynex, Inc., Q3 2023 Earnings Call, Oct 26, 2023
Zynex, Inc. Provides Earnings Guidance for Fourth Quarter and Full Year of 2023 CI
Chart Zynex, Inc.
More charts
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Company’s devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Company’s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.45 USD
Average target price
18.98 USD
Spread / Average Target
+65.76%
Consensus
  1. Stock Market
  2. Equities
  3. ZYXI Stock
  4. News Zynex, Inc.
  5. B. Riley Raises Zynex's Price Target to $12.50 From $11, Notes Solid Q3 Execution with Momentum Expected Into Q4; Keeps Buy Rating